Full Text
The Acceptance Of Morbidity Endpoints In The Amnog Process In Germany- Are There Greater Hurdles For Substances Within Oncology?

Abstract

Authors

K Bakker T Volmer

Back to Volume 18, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×